SCHEMBL3620570

SCHEMBL3620570

COc1ccc(-c2cnn3cc(C(=O)O)cnc23)cc1OC

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAK O14976 1/20 0.64
PRKAB2 O43741 1/20 0.49
PRKAG1 P54619 1/20 0.49
PRKAA2 P54646 1/20 0.49
PRKAA1 Q13131 1/20 0.49
PRKAG3 Q9UGI9 1/20 0.49
PRKAG2 Q9UGJ0 1/20 0.49
PRKAB1 Q9Y478 1/20 0.49
MAPT P10636 4/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
MEN1 O00255 1/20 0.48
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
KMT2A Q03164 1/20 0.48
LMNA P02545 1/20 0.47
POLB P06746 1/20 0.47
KDR P35968 5/20 0.46
EGLN1 Q9GZT9 1/20 0.46
ACVR2A P27037 3/20 0.46
TGFBR2 P37173 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3615760 0.81 GAK (0.53) GAKPRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL3563176 0.76 HPGD (0.71) MEN1NPC1RAB9AKMT2AKDR
SCHEMBL13126019 0.74 KDR (0.76) GAKPRKAB1KMT2AKDREGLN1
SCHEMBL23162132 0.71 GAK (0.55) GAKPRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL3620632 0.71 LCK (0.53) PRKAB1KDRTGFBR2TGFBR1ACVR1
SCHEMBL6244003 0.70 CA12 (0.71) RAB9ALMNACA12CA1CA2
SCHEMBL30613542 0.69 KDR (0.44) GAKPRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL23162194 0.69 TGFBR1 (0.54) GAKPRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL5416682 0.69 KDR (0.67) GAKPRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL3758736 0.68 MAP4K4 (0.57) GAKPRKAG1PRKAA1PRKAB1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100069395-A1 Pyrazolo[1,5-a]pyrimidine-3-carboxylic acid compounds as protein kinase inhibitors IMBACH PATRICIA 2010-03-18 US claimed
EP-2079745-A1 3-AMINOCARBONYI-SUBSTITUTED FUSED PYRAZOLO-DERIVATIVES AS PROTEIN KINASE MODULATORS Novartis AG (CH) 2009-07-22 EP claimed
WO-2008052964-A1 3-AMINOCARBONYI-SUBSTITUTED FUSED PYRAZOLO-DERIVATIVES AS PROTEIN KINASE MODULATORS NOVARTIS AG (CH) 2008-05-08 WO claimed
EP-1918291-A1 3-Aminocarbonyl-substituted fused pyrazolo-derivatives as protein kinase modulators Novartis AG (CH) 2008-05-07 EP claimed
US-20100069395-A1 Pyrazolo[1,5-a]pyrimidine-3-carboxylic acid compounds as protein kinase inhibitors IMBACH PATRICIA 2010-03-18 US disclosed
EP-2079745-A1 3-AMINOCARBONYI-SUBSTITUTED FUSED PYRAZOLO-DERIVATIVES AS PROTEIN KINASE MODULATORS Novartis AG (CH) 2009-07-22 EP disclosed
WO-2008052964-A1 3-AMINOCARBONYI-SUBSTITUTED FUSED PYRAZOLO-DERIVATIVES AS PROTEIN KINASE MODULATORS NOVARTIS AG (CH) 2008-05-08 WO disclosed
EP-1918291-A1 3-Aminocarbonyl-substituted fused pyrazolo-derivatives as protein kinase modulators Novartis AG (CH) 2008-05-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069395-A1 Pyrazolo[1,5-a]pyrimidine-3-carboxylic acid compounds as protein kinase inhibitors PRKCA, PRKACA, MAP3K19 GAK 95/4885PRKAB2 50/4885PRKAG1 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.